Department of Respiratory Medicine, Kanazawa University, Kanazawa 920-8641, Ishikawa, Japan.
Department of Respiratory Medicine, Kanazawa University, Kanazawa 920-8641, Ishikawa, Japan.
Cancer Treat Res Commun. 2021;28:100399. doi: 10.1016/j.ctarc.2021.100399. Epub 2021 May 15.
The coronavirus disease 2019 (COVID-19) pandemic has triggered a sudden global change in healthcare systems. Cancer patients have a higher risk of death from COVID-19 in comparison to patients without cancer. Many studies have stated that various factors, such as older age, frequent exposure to healthcare, and higher smoking rates are responsible for the complications of COVID-19. We hypothesize that side effects of chemotherapy, such as cellular senescence, could worsen COVID-19. Given this situation, in this review, we highlight the updated findings of research investigating the impact of cellular senescence on COVID-19 complications and explored potential therapeutic targets for eliminating senescent cells during the COVID-19 pandemic.
2019 冠状病毒病(COVID-19)大流行引发了全球医疗体系的突然变革。与无癌症患者相比,癌症患者因 COVID-19 而死亡的风险更高。许多研究表明,各种因素,如年龄较大、频繁接触医疗保健和较高的吸烟率,是导致 COVID-19 并发症的原因。我们假设化疗的副作用,如细胞衰老,可能会使 COVID-19 恶化。鉴于这种情况,在本综述中,我们强调了研究细胞衰老对 COVID-19 并发症影响的最新发现,并探讨了在 COVID-19 大流行期间消除衰老细胞的潜在治疗靶点。